951626-54-3 Usage
Uses
Used in Pharmaceutical Industry:
6-(4-Fluorophenyl)morpholin-3-one is used as a reagent for the synthesis of Aprepitant (A729800), a selective neurokinin-1 (NK-1) receptor antagonist. 6-(4-fluorophenyl)morpholin-3-one is essential in the development of antiemetic medications, which help in managing nausea and vomiting.
As an Antiemetic Agent:
6-(4-Fluorophenyl)morpholin-3-one contributes to the synthesis of Aprepitant, which is used as an antiemetic agent. Aprepitant works by blocking the neurokinin-1 (NK-1) receptor, thereby reducing the sensation of nausea and vomiting.
In Drug Metabolism Studies:
6-(4-Fluorophenyl)morpholin-3-one is involved in the synthesis of Aprepitant, which has been studied for its metabolism in human liver microsomes. It has been found that Aprepitant is primarily metabolized by CYP3A4, with minor metabolism by CYP1A2 and CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2E1. This information is crucial for understanding the drug's pharmacokinetics and potential drug-drug interactions.
Check Digit Verification of cas no
The CAS Registry Mumber 951626-54-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,1,6,2 and 6 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 951626-54:
(8*9)+(7*5)+(6*1)+(5*6)+(4*2)+(3*6)+(2*5)+(1*4)=183
183 % 10 = 3
So 951626-54-3 is a valid CAS Registry Number.
951626-54-3Relevant academic research and scientific papers
DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY
-
, (2018/11/21)
The disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof: The disclosure also provides processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them, and their use
Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists
Micheli, Fabrizio,Cremonesi, Susanna,Semeraro, Teresa,Tarsi, Luca,Tomelleri, Silvia,Cavanni, Paolo,Oliosi, Beatrice,Perdon, Elisabetta,Sava, Anna,Zonzini, Laura,Feriani, Aldo,Braggio, Simone,Heidbreder, Christian
, p. 1329 - 1332 (2016/02/23)
A new series of morpholine derivatives has been identified as selective DA D3 receptor antagonists; their in vitro profile and pharmacokinetic data are provided.
